Please login to the form below

Not currently logged in
Email:
Password:

K-V resumes limited manufacturing

K-V Pharmaceutical has received permission from the US Food and Drug Administration to resume production of its potassium chloride products

K-V Pharmaceutical Company, which has encountered regulatory and legal difficulties over the past few years, has received permission from the US Food and Drug Administration (FDA) to resume production of its potassium chloride products following a successful inspection of the company's manufacturing facilities.

K-V recalled all of the products it manufactures early last year after FDA inspections turned up manufacturing problems including oversized tablets that could result in overdoses. The company also halted manufacturing and shipping of further products at that time.

The speciality pharma firm's consent decree with the FDA makes resumption of manufacturing and shipment of the products contingent on successful inspections.

The results of an inspection conducted in mid-August have allowed the company to begin producing the potassium chloride products Micro-K 10mEq and Micro-K 8mEq, which are indicated for the prevention and treatment of hypokalaemia, a condition characterised by low serum potassium that can lead to cardiovascular complications and impaired muscle function.

K-V said it intends to begin shipping the potassium chloride products next week, and that the FDA is expected to conduct additional inspections to decide whether other products may also be returned to the marketplace in the near future.

K-V markets its products through Ther-Rx Corporation, its branded drug subsidiary. Its portfolio includes the estrogen therapy Evamist (estradiol transdermal spray), which is intended to treat hot flashes, and the anti-infectives Clindesse and Gynazole-1, which treat bacterial vaginosis and yeast infections.

The company's generic drug subsidiary Ethex ceased operations earlier this year after pleading guilty to criminal charges brought by the US Department of Justice over its failure to notify authorities about potentially dangerous manufacturing problems.

10th September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
IPG Health Medical Communications

We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....